Genialis™ krasID

krasID is a platform that incorporates over 20 AI/ML biomodules of KRAS-associated biology

  • Identify patients most likely to benefit from your KRAS inhibitor, and understand why

  • Predict the duration of response

  • Elucidate early disease progression in KRAS-mutated cancers treated with KRAS inhibitors

krasID generates a fundamentally new type of biomarker that reflects underlying biological states, not just genetic variants

Customizable for different KRAS inhibitors, tissue types, or treatment combinations, krasID can be tuned to match your specific preclinical or clinical context. The resulting biomarkers serve to differentiate your compound against a crowded field of competitors.

Case Study

A krasID predictor accurately stratifies KRASi-eligible patients by clinical response

  • Real World Data
    Patient data from real-world sotorasib-treated cohorts mirror those in the CodeBreaK100/200 clinical trials

  • Longer Time on Treatment
    Patients identified as responders with krasID remained on sotorasib nearly 50% longer than the entire cohort of G12C-selected patients

  • Accurate predictions
    KrasID predicts response with >94% accuracy in preclinical models and >80% accuracy in real-world patients

  • KM plot of predicted benefit to sotorasib in a NSCLC RWE cohort

  • KM plot of predicted benefit to sotorasib in a NSCLC RWE cohort

  • KM plot of predicted benefit to sotorasib in a NSCLC RWE cohort

krasID biomarker white paper cover

Want to learn more?

Explore the full story behind the science and innovation of krasID. Inside, you’ll find:

  • Why RNA phenomarkers matter

  • How krasID leverages the Supermodel

  • How the algorithms perform on validated real-world results

  • How krasID can be tuned for your particular compound and questions

ASCO 2025: Sotorasib Response Predictor

At ASCO in May 2025, we presented Genialis™ krasID, an RNA-based biomarker capable of predicting response duration to the KRAS inhibitor sotorasib and identifying clinically actionable resistance mechanisms.

AACR 2025: Genialis™ Supermodel for KRAS Biomarker Discovery

At AACR in May 2025, we presented the Genialis™ Supermodel, a foundation model of cancer biology used to derive novel biomarkers for diagnosis, clinical development, and treatment decision-making in oncology, illustrated through our KRAS response biomarker.

RAS Summit 2024: krasID for KRAS Therapy Stratification

At the 6th Annual RAS-Targeted Drug Development Summit in September 2024, we presented Genialis™ krasID, a biology-driven machine learning biomarker designed to predict response to KRAS inhibitors and guide monotherapy or combination therapy strategies.